Published in:
Open Access
01-11-2018 | Endocrine Surgery
Pediatric pituitary adenomas in Northeast Mexico. A follow-up study
Published in:
Endocrine
|
Issue 2/2018
Login to get access
Abstract
Purpose
To review incidence, treatment and outcome of pediatric pituitary adenomas (PAs).
Methods
A follow-up study patients with the age of ≤19 years old who were treated from 1995 to 2015 in Mexico.
Results
Out of 1244 diagnosed PA, 43 patients were children (35 females, 8 males) with a mean age of 17.2 years. The majority were macroadenomas (70%) with prolactinomas (PRL) dominating (63%) followed by non-functioning adenomas (21%). In total, 40% were diagnosed as invasive. Growth hormone (GH) secreting adenomas, adrenocorticotropic hormone secreting and mixed GH-PRL secreting were rare. The treatment modalities were dopamine agonists and surgery. The average treatment time was 44 months with an average follow-up period of 104 months. Sixty-eight percent (27/40) of the patients had complete response after long time follow-up. Thirty-one percent did not respond to treatment whereof three patients died due to advanced disease and late intervention. The principal causes for treatment failure were treatment resistance, late intervention and poor patient compliance.
Conclusions
Sixty eight percent had complete treatment response without any sign of disease, while ~31% did not respond to treatment or did not comply to follow up/treatment. Optimized early diagnose, treatment methods with early intervention, long time follow-up and with better measures for patient compliance should improve outcomes.